0

0

0

0

0

0

0

0

0

videos | IST

Market guru SP Tulsian remains cautious on these pharma stocks

Mini

SP Tulsian of sptulsian.com is a renowned market analyst, he provided his analysis on the fundamental side of the market as well as specific stocks and sectors in an interview with CNBC-TV18.

In his latest analysis and commentary, stock market expert SP Tulsian of Sptulsian.com gave his take on specific stocks and sectors in an interview with CNBC-TV18.
A fundamental analyst with more than three decades of experience, Tulsian has an acute sense of logic and is respected for his frank and forthright views.
“It is strange to see that Titan management is seen cautious and have reduced their guidance; but the media and many experts seem quite bullish and I don’t understand that. Things seem to be quite expensive for jewellery stocks, that is Titan. Again people call it a Tata Group company, however, I call it a joint sector company in which the Tamil Nadu state government is holding the larger chunk of the promoter stake of 53 percent. They hold 28 percent, Tatas hold 25 percent. So there are many reasons that there is no point in taking a call on Titan, that too after having seen such a muted guidance by the management for the second half of FY20,” he said.
“Bajaj Electrical share has lost its theme and momentum after the unfortunate death of Shekhar Bajaj's son who was the managing director of the company about a year back. Since then this company has not been back on track. On the consumer durable front also they seem to be lacking. So one has to see the results but definitely the disappointment is seen getting reflected on the numbers. One has to see the engineering or the engineering, procurement and construction division because losses must have come from there for the stock in this quarter,” Tulsian noted.
Speaking about Cipla, the analyst said, “If I focus on Q2 numbers, definitely the numbers are good. We are still not taking a buying call on Lupin, Cipla and Sun Pharmaceuticals because probably the things may not be consistent. We have been selective buyers in pharma stocks and it is not on our radar. But in terms of Q2 numbers, there are no complaints, in fact the numbers are better.”
Tulsian is not disappointed with the Exide Industries numbers, is  keeping an eye on Amara Raja Batteries, and maintains a cautious view on tyre stocks as Apollo Tyres numbers are bad.